First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study-Reference-Cited by-同舟云学术

First‐line pembrolizumab for non–small cell lung cancer patients with PD‐L1 ≥50% in a multicenter real‐life cohort: The PEMBREIZH study

Published:2020-04 Issue:7 Volume:9 Page:2309-2316
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Amrane Karim¹^ORCID,Geier Margaux¹,Corre Romain²,Léna Hervé²,Léveiller Guillaume³,Gadby Florence⁴,Lamy Régine⁵,Bizec Jean‐Louis⁶,Goarant Eric⁷,Robinet Gilles¹,Gouva Sylvie¹,Quere Gilles¹,Abgral Ronan⁸,Schick Ulrike¹,Bernier Cyril⁹,Chouaid Christos¹⁰^ORCID,Descourt Renaud¹

Affiliation:

1. Oncology Department CHRU Brest Brest France

2. Pulmonology Department CHU Hôpital Ponchaillou Rennes France

3. Pulmonology Department CH Yves le Foll Saint Brieuc France

4. Pulmonology Department CH des Pays Morlaix Morlaix France

5. Oncology Department CH Bretagne Sud Lorient France

6. Pulmonology Department CH Bretagne Atlantique Vannes France

7. Pulmonology Department CH Saint‐Malo Saint Malo France

8. Nuclear Medicine Department CHRU Brest Brest France

9. Pulmonology Department CH René Pleven Dinan France

10. Pulmonology Department CHI Créteil Créteil France

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2806

Reference30 articles.

1. Cancer Today [Internet]. [cité 16 juin 2019]. Disponible sur:http://gco.iarc.fr/today/online-analysis-table?v=2018&mode=cancer&mode_population=continents&population=900&populations=900&key=asr&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&group_cancer=1&include_nmsc=1&include_nmsc_other=1.

2. Multidisciplinary Management of Lung Cancer

3. Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

5. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab monotherapy survival benefits in metastatic non-small-cell lung cancer: a systematic review of real-world data;Discover Oncology;2024-07-24

2. Effectiveness and safety of pembrolizumab as first-line treatment for non-small cell lung cancer in real clinical practice;Journal of Oncology Pharmacy Practice;2024-07-23

3. Comparison of the efficacy and safety of domestically produced tislelizumab, camrelizumab, and imported pembrolizumab in the treatment of advanced NSCLC: a real-world retrospective study;Clinical and Translational Oncology;2024-06-27

4. Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study);Cancers;2024-05-08

5. Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer;FUTURE ONCOL;2024